Antimicrobial Agents Practice Questions

Q: Which of the following antimicrobial agents is not bacteriostatic?

Vancomycin. ### Explanation **Core Concept:** Antimicrobial agents are classified based on their effect on bacteria: **Bacteriostatic** drugs inhibit growth and replication (requiring the host’s immune system to clear the infection), while **Bactericidal** drugs actively kill the bacteria. **Why Vancomycin is the Correct Answer:** **Vancomycin** is a glycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to the **D-Ala-D-Ala** terminus of nascent peptidoglycan chains. Like most cell wall synthesis inhibitors (e.g., Penicillins, Cephalosporins), it is **bactericidal**. It causes cell lysis, making it the only bactericidal agent among the options provided. **Analysis of Incorrect Options:** * **Linezolid (Option A):** An oxazolidinone that inhibits protein synthesis by binding to the 50S subunit (specifically preventing the formation of the 70S initiation complex). It is **bacteriostatic** against Staphylococci and Enterococci (though it shows bactericidal activity against *S. pneumoniae*). * **Clindamycin (Option B):** A lincosamide that inhibits protein synthesis by binding to the 50S ribosomal subunit. It is primarily **bacteriostatic**. * **Erythromycin (Option C):** A macrolide that inhibits protein synthesis at the 50S subunit. Macrolides are classic examples of **bacteriostatic** agents. **NEET-PG High-Yield Pearls:** * **Mnemonic for Bactericidal drugs:** "**V**ery **F**inely **P**en**C**illed **A**t **B**edside" (**V**ancomycin, **F**luoroquinolones, **P**enicillins, **C**ephalosporins, **A**minoglycosides, **B**acitracin). * **Exception:** Aminoglycosides are the only protein synthesis inhibitors that are primarily bactericidal. * **Clinical Note:** Vancomycin is the drug of choice for **MRSA**. Rapid IV infusion can cause "**Red Man Syndrome**" due to histamine release (not an allergy).

Q: Which anti-tuberculosis agent causes orange-colored urine?

Rifampicin. **Explanation:** **Rifampicin** is a semi-synthetic derivative of rifamycin and a key bactericidal drug in the DOTS regimen. The correct answer is Rifampicin because it is a **zwitterionic compound with a characteristic red-orange color**. After administration, it is excreted through urine, sweat, tears, and saliva, imparting a harmless **orange-red discoloration** to these body fluids. **Why the other options are incorrect:** * **Isoniazid (INH):** Its primary side effects are peripheral neuropathy (due to Vitamin B6 deficiency) and hepatotoxicity. It does not cause pigment changes in secretions. * **Streptomycin:** An aminoglycoside that primarily causes ototoxicity (vestibular damage) and nephrotoxicity. * **Pyrazinamide:** Known for causing hyperuricemia (leading to gouty arthritis) and hepatotoxicity, but it does not discolor urine. **Clinical Pearls for NEET-PG:** 1. **Patient Counseling:** Always advise patients starting Rifampicin about orange urine to prevent unnecessary anxiety and improve compliance. It can also permanently stain soft contact lenses. 2. **Mechanism of Action:** Rifampicin inhibits **DNA-dependent RNA polymerase**, thereby blocking bacterial RNA synthesis. 3. **Enzyme Induction:** Rifampicin is a potent **Cytochrome P450 inducer**, leading to significant drug interactions (e.g., reducing the efficacy of oral contraceptives and warfarin). 4. **Resistance:** Resistance develops rapidly if used as monotherapy due to mutations in the *rpoB* gene.

Q: What is the drug of choice for brucellosis?

Doxycycline. **Explanation:** **Brucellosis** is a zoonotic infection caused by *Brucella* species, which are facultative intracellular organisms. Effective treatment requires drugs with high intracellular penetration and a low risk of relapse. **Why Doxycycline is the Correct Answer:** **Doxycycline** is the backbone of brucellosis treatment. Due to its high lipid solubility, it achieves excellent intracellular concentrations, which is essential for eradicating the bacteria residing within macrophages. However, when used as monotherapy, relapse rates are high. Therefore, the **WHO-recommended regimen** (and the gold standard) is **Doxycycline (100 mg BID for 6 weeks) + Rifampin (600–900 mg/day for 6 weeks)**. Alternatively, Doxycycline can be combined with Streptomycin (IM for 2–3 weeks). **Why Other Options are Incorrect:** * **A. Chloramphenicol:** While it has good intracellular penetration, it is not a first-line agent due to the risk of bone marrow toxicity (aplastic anemia) and higher relapse rates compared to tetracyclines. * **B. Erythromycin:** Macrolides have poor *in vitro* activity against *Brucella* and are clinically ineffective for this condition. * **D. Cefuroxime:** Second-generation cephalosporins do not have the necessary intracellular reach or specific activity required to treat brucellosis. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice (DOC):** Doxycycline + Rifampin (for 6 weeks). * **In Pregnancy/Children (<8 years):** Doxycycline is contraindicated. The DOC is **Trimethoprim-Sulfamethoxazole (TMP-SMZ) + Rifampin**. * **Neurobrucellosis/Endocarditis:** Requires a triple regimen (Doxycycline + Rifampin + Aminoglycoside/Ceftriaxone) for a prolonged duration (3–6 months). * **Common Presentation:** Undulant fever (fever that rises and falls like waves), profuse sweating, and hepatosplenomegaly.

Q: All of the following are used in the treatment of visceral leishmaniasis except:

Hydroxychloroquine. **Explanation:** Visceral Leishmaniasis (Kala-azar) is caused by *Leishmania donovani*. The correct answer is **Hydroxychloroquine**, as it is an antimalarial and immunomodulatory agent used in conditions like Malaria, SLE, and Rheumatoid Arthritis, but it has **no clinical efficacy** against *Leishmania* species. **Analysis of Options:** * **Miltefosine:** This is the **first and only oral drug** approved for visceral leishmaniasis. It acts by interfering with cell signaling pathways and membrane synthesis. It is highly effective but contraindicated in pregnancy due to teratogenicity. * **Paromomycin:** An aminoglycoside antibiotic that inhibits protein synthesis. It is used as an injectable treatment for Kala-azar and is known for being cost-effective, though it carries risks of ototoxicity and nephrotoxicity. * **Sitamaquine:** An oral 8-aminoquinoline derivative (currently under investigation/limited use) that has shown efficacy against the visceral form of the disease by interfering with the parasite's mitochondrial function. **High-Yield NEET-PG Pearls:** 1. **Drug of Choice:** **Liposomal Amphotericin B** is currently the preferred treatment due to its high efficacy and low toxicity (single-dose regimen is often used in India). 2. **Miltefosine:** Must be avoided in pregnancy; female patients should use contraception for 5 months post-treatment. 3. **Sodium Stibogluconate (Pentavalent Antimonials):** Formerly the mainstay of treatment, but now largely abandoned in regions like Bihar, India, due to widespread resistance and cardiotoxicity (Q-T prolongation). 4. **Post-Kala-azar Dermal Leishmaniasis (PKDL):** Usually treated with prolonged courses of Miltefosine or Amphotericin B.

Q: Which of the following drug classes is known to cause nephrotoxicity?

Aminoglycosides. **Explanation:** **Aminoglycosides (Option B)** are the correct answer as they are notoriously associated with **dose-dependent nephrotoxicity**. The underlying mechanism involves the accumulation of the drug within the proximal convoluted tubule (PCT) cells. Aminoglycosides are filtered by the glomerulus and then reabsorbed by the tubular epithelium via the megalin-cubilin transport system. Once inside, they cause lysosomal rupture and oxidative stress, leading to **Acute Tubular Necrosis (ATN)**. This is typically reversible upon discontinuation of the drug. **Why other options are incorrect:** * **Doxycycline (Option A):** Unlike other tetracyclines, doxycycline is primarily excreted via the biliary route (feces), making it the safest tetracycline in patients with renal failure. It does not cause nephrotoxicity. * **Erythromycin (Option B):** This macrolide is primarily metabolized by the liver and excreted in bile. Its chief side effects are GI upset (motilin receptor agonism) and cholestatic hepatitis, not renal damage. * **Rifampicin (Option D):** While it can rarely cause interstitial nephritis, its hallmark side effects are hepatotoxicity and the harmless orange-red discoloration of body fluids. **High-Yield Clinical Pearls for NEET-PG:** 1. **Nephrotoxicity vs. Ototoxicity:** Aminoglycosides cause both. Neomycin is the most nephrotoxic; Streptomycin is the least. 2. **Monitoring:** To minimize toxicity, **Once-Daily Dosing** (Extended Interval Dosing) is preferred due to the "Post-Antibiotic Effect." 3. **Drug Interactions:** Risk of nephrotoxicity increases when aminoglycosides are co-administered with Loop Diuretics (e.g., Furosemide), Vancomycin, or Cisplatin. 4. **Rule of Thumb:** Aminoglycosides are "Mean" (NEphrotoxic and Ototoxic).

Q: What is the treatment of choice for benign tertian malaria?

Chloroquine. **Explanation:** **Benign tertian malaria** is caused by *Plasmodium vivax* and *Plasmodium ovale*. The standard treatment of choice for these species remains **Chloroquine**, as it is highly effective against the erythrocytic stages of the parasite in most regions. 1. **Why Chloroquine is Correct:** Chloroquine is a 4-aminoquinoline that concentrates in the acidic food vacuole of the parasite, inhibiting heme polymerase. This leads to the accumulation of toxic heme, killing the parasite. For *P. vivax* and *P. ovale*, it rapidly clears the fever and parasitemia. 2. **Why other options are incorrect:** * **Sulfamethoxazole-pyrimethamine (Option A):** Primarily used for chloroquine-resistant *P. falciparum*. It is not the first-line agent for benign tertian malaria due to slower action and increasing resistance. * **Quinine (Option B):** Reserved for severe or complicated malaria and chloroquine-resistant cases. It has a narrow therapeutic index and significant side effects (Cinchonism). * **Mefloquine (Option C):** Used for prophylaxis in travelers or as a second-line treatment for resistant *P. falciparum*. It is associated with neuropsychiatric side effects. **High-Yield Clinical Pearls for NEET-PG:** * **Radical Cure:** Chloroquine only treats the blood stages. To prevent relapse from dormant liver stages (**hypnozoites**), **Primaquine** must be administered for 14 days. * **G6PD Screening:** Always screen for G6PD deficiency before starting Primaquine to avoid acute hemolysis. * **Drug of Choice for Pregnancy:** Chloroquine is safe and remains the drug of choice for malaria in pregnancy (all trimesters) for sensitive strains. * **Malignant Tertian Malaria:** Refers to *P. falciparum*, which is typically treated with ACT (Artemisinin-based Combination Therapy).

Q: All of the following drugs can be used for the management of malaria due to chloroquine-resistant vivax except?

Fluoroquinolones. **Explanation:** The management of chloroquine-resistant *Plasmodium vivax* (CRPV) has become a clinical challenge in certain endemic regions (e.g., Indonesia, parts of India). According to WHO and National Guidelines, the treatment strategy for CRPV mirrors that of *P. falciparum*. **Why Fluoroquinolones are the Correct Answer:** While some fluoroquinolones (like Ciprofloxacin or Levofloxacin) exhibit weak anti-plasmodial activity *in vitro*, they are **not clinically recommended** or effective for the management of malaria. They lack the potency required to clear parasites effectively and are never used as standard therapy for any form of malaria. **Analysis of Other Options:** * **Artesunate (Option C):** ACT (Artemisinin-based Combination Therapy) is the current **first-line treatment** for chloroquine-resistant malaria (both *falciparum* and *vivax*). * **Quinine (Option A):** Historically the mainstay for resistant malaria, it remains an effective alternative, especially in severe cases or when ACTs are unavailable. * **Doxycycline (Option B):** It is a slow-acting blood schizonticide used as an **adjunct** to Quinine to ensure complete parasite clearance and prevent recrudescence. **High-Yield Clinical Pearls for NEET-PG:** 1. **First-line for CRPV:** ACT (e.g., Artesunate + Lumefantrine) is preferred. 2. **Radical Cure:** Regardless of the drug used for blood schizonts, **Primaquine** (for 14 days) must be added to treat hypnozoites in the liver to prevent relapse in *P. vivax*. 3. **Tafenoquine:** A newer single-dose alternative to Primaquine for radical cure (requires G6PD screening). 4. **Mechanism of Chloroquine Resistance:** Primarily due to mutations in the **PvCRT-o** gene (ortholog to PfCRT) or **PvMDR1** gene.

Q: Which among the following drugs is safest in a patient allergic to penicillin?

Aztreonam. **Explanation:** The correct answer is **Aztreonam**. **Why Aztreonam is the correct choice:** Aztreonam is a **Monobactam**. Unlike other beta-lactams, it possesses a unique monocyclic beta-lactam ring that does not share the common bicyclic nucleus found in penicillins and cephalosporins. Consequently, there is **no cross-reactivity** between Aztreonam and other beta-lactams (except for Ceftazidime, with which it shares a side chain). It is considered the drug of choice when a patient with a documented severe penicillin allergy requires coverage for Gram-negative aerobic bacteria. **Why the other options are incorrect:** * **Cephalexin (1st Gen Cephalosporin) & Cefepime (4th Gen Cephalosporin):** Cephalosporins share a similar structural nucleus with penicillins. In patients with a history of Type-1 hypersensitivity (anaphylaxis) to penicillin, there is a significant risk (approx. 1-10%) of cross-reactivity. * **Imipenem (Carbapenem):** Carbapenems also share a bicyclic ring structure. While the cross-reactivity rate is lower than previously thought (around 1%), it is still significantly higher than that of Aztreonam, making it less "safe" in the context of this question. **High-Yield Clinical Pearls for NEET-PG:** * **Spectrum of Aztreonam:** It is active **only against Gram-negative aerobes** (e.g., *Pseudomonas*, *E. coli*). It has no activity against Gram-positives or anaerobes ("Aztreonam is a Lone Ranger against Gram-negatives"). * **Exception to the Rule:** Aztreonam should be avoided in patients allergic to **Ceftazidime** due to identical side chains. * **Safe Alternatives:** For penicillin-allergic patients, Macrolides (Erythromycin) or Clindamycin are often used for Gram-positive coverage, while Aztreonam is used for Gram-negative coverage.

Q: What is the most common side effect of miltefosine?

Vomiting and diarrhea. **Explanation:** **Miltefosine** is a landmark drug in the treatment of Leishmaniasis as it is the **first and only oral agent** effective against Visceral Leishmaniasis (Kala-azar). It is an alkylphosphocholine analogue that acts by interfering with cell membrane signaling and inducing apoptosis in the *Leishmania* parasite. 1. **Why Option A is correct:** The most frequent adverse effects of miltefosine are **gastrointestinal (GI) disturbances**. Approximately 40–60% of patients experience **vomiting and diarrhea**. These symptoms are usually dose-dependent, occur early in the treatment course, and are generally transient or manageable with antiemetics and hydration. 2. **Why other options are incorrect:** * **Dermatitis (B):** While skin rashes can occur, they are rare and not the primary side effect. * **Hepatotoxicity (C):** Transient elevations in liver enzymes (ALT/AST) can occur, but this is significantly less common than GI distress. * **Nephrotoxicity (D):** Miltefosine can cause a transient rise in creatinine levels, but it is not primarily known for nephrotoxicity (unlike Amphotericin B, another drug used for Leishmaniasis). **High-Yield Clinical Pearls for NEET-PG:** * **Teratogenicity:** Miltefosine is strictly **contraindicated in pregnancy** due to its potent teratogenic effects. Female patients of reproductive age must use effective contraception during and for **5 months after** treatment (due to the drug's long half-life). * **Drug of Choice:** It is a primary treatment for both Visceral and Post-Kala-azar Dermal Leishmaniasis (PKDL). * **Mechanism:** It inhibits **phospholipase C** and protein kinase C, disrupting the parasite's lipid metabolism.

Question 1

Which of the following antimicrobial agents is not bacteriostatic?

Accepted Answer

Vancomycin

Answer

Linezolid

Answer

Clindamycin

Answer

Erythromycin

Question 2

Which anti-tuberculosis agent causes orange-colored urine?

Accepted Answer

Rifampicin

Answer

Isoniazid

Answer

Streptomycin

Answer

Pyrazinamide

Question 3

What is the drug of choice for brucellosis?

Accepted Answer

Doxycycline

Answer

Chloramphenicol

Answer

Erythromycin

Answer

Cefuroxime

Question 4

All of the following are used in the treatment of visceral leishmaniasis except:

Accepted Answer

Hydroxychloroquine

Answer

Sitamaquine

Answer

Paromomycin

Answer

Miltefosine

Question 5

Which of the following drug classes is known to cause nephrotoxicity?

Accepted Answer

Aminoglycosides

Answer

Doxycycline

Answer

Erythromycin

Answer

Rifampicin

Question 6

What is the treatment of choice for benign tertian malaria?

Accepted Answer

Chloroquine

Answer

Sulfamethoxazole-pyrimethamine

Answer

Quinine

Answer

Mefloquine

Question 7

All of the following drugs can be used for the management of malaria due to chloroquine-resistant vivax except?

Accepted Answer

Fluoroquinolones

Answer

Quinine

Answer

Doxycycline

Answer

Artesunate

Question 8

The development of resistance to conventional treatment has led WHO to recommend the use of combination therapies containing artemisinin derivatives (artemisinin-based combination therapies or ACTs). Which of the following combination therapies is NOT recommended if such resistance is suspected?

Accepted Answer

Artesunate plus quinine

Answer

Artemether plus lumefantrine

Answer

Artesunate plus pyrimethamine-sulfadoxine

Answer

Artesunate plus mefloquine

Question 9

Which among the following drugs is safest in a patient allergic to penicillin?

Accepted Answer

Aztreonam

Answer

Cephalexin

Answer

Imipenem

Answer

Cefepime

Question 10

What is the most common side effect of miltefosine?

Accepted Answer

Vomiting and diarrhea

Answer

Dermatitis

Answer

Hepatotoxicity

Answer

Nephrotoxicity

Antimicrobial Agents — MCQs

Antimicrobial Agents — MCQs

On this page

Practice by Chapter

Want unlimited practice?